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Background and Purpose
The paradigm that GPCRs are able to prolong or initiate cellular signalling through
intracellular receptors recently emerged. Melatonin binds to G protein‐coupled MT1
and MT2 receptors. In contrast to most other hormones targeting GPCRs, melatonin
and its synthetic analogues are amphiphilic molecules easily penetrating into cells,
but the existence of intracellular receptors is still unclear mainly due to a lack of
appropriate tools.
Experimental Approach
We therefore designed and synthesized a series of hydrophilic melatonin receptor
ligands coupled to the Cy3 cyanin fluorophore to reliably monitor its inability to
penetrate cells. Two compounds, one lipophilic and one hydrophilic, were then
functionally characterized in terms of their affinity for human and murine melatonin
receptors expressed in HEK293 cells and their signalling efficacy.
Key Results
Among the different ligands, ICOA‐13 showed the desired properties as it was cell‐
impermeant and bound to human and mouse MT1 and MT2 receptors. ICOA‐13
showed differential activities on melatonin receptors ranging from partial to full
agonistic properties for the Gi/cAMP and ERK pathway and β‐arrestin 2 recruitment.
Notably, ICOA‐13 enabled us to discriminate between Gi/cAMP signalling of the MT1
receptor initiated at the cell surface and neuronal mitochondria.
Conclusions and Implications
We report here the first cell‐impermeant melatonin receptor agonist, ICOA‐13, which
allows us to discriminate between signalling events initiated at the cell surface and
intracellular compartments. Detection of mitochondrial MT1 receptors may have an
important impact on the development of novel melatonin receptor ligands relevant
for neurodegenerative diseases, such as Huntington disease.
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